The first line therapy by Teikyo-NKT before chemotherapy to patients with advanced non-small cell lung cancer.

The first line therapy by Teikyo-NKT before chemotherapy to patients with advanced non-small cell lung cancer. - The first line therapy by Teikyo-NKT before chemotherapy to patients with advanced non-small cell lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027782

Enrollment

Registered

2017-06-21

Start date

2017-06-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Therapy by Teikyo-NKT before chemotherapy to advanced non-small cell lung cancer.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: non small cell lung cancer stage 3B 4 EGFR gene mutation negative ALK gene mutation negative PS 0 1

Exclusion criteria

Exclusion criteria: autoimmune disease HBsAg + HCVAb + HTLV-1Ab + HIVAb + brain meta, carcinomatous pleurisy, carcinomatous peritonitis, carcinomatous meningitis (uncntrollable) serious lung disease (interstitial pneumonia etc) medication of steroid or immunosuppressant multicentric cancer

Design outcomes

Primary

Measure	Time frame
Feasibility and safety of Teikyo-NKT before chemothaepy to advanced non-small cell lung cancer.	—

Secondary

Measure	Time frame
Efficacy of Teikyo-NKT before chemothaepy to advanced non-small cell lung cancer.	—

Countries

Japan

Contacts

Public ContactMasaaki Hagiya

Teikyo University Chiba Medeical Ceater internal medicine (respirology)

hagiyam@med.teikyo-u.acjp0436-62-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026